Clinical Trials in Munich, Germany

165 recruiting

Showing 120 of 282 trials

Recruiting
Phase 3

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Cervical Cancer
Merck Sharp & Dohme LLC686 enrolled240 locationsNCT06459180
Recruiting
Phase 3

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC1,530 enrolled288 locationsNCT06393374
Recruiting
Not Applicable

Ultra-high-caloric, Fatty Diet in ALS

Amyotrophic Lateral Sclerosis
University of Ulm392 enrolled23 locationsNCT06280079
Recruiting
Phase 3

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Early Breast Cancer
Novartis Pharmaceuticals1,400 enrolled205 locationsNCT05827081
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

Bristol-Myers Squibb586 enrolled123 locationsNCT06976203
Recruiting
Phase 3

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Gilead Sciences1,514 enrolled339 locationsNCT05633654
Recruiting
Phase 3

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Oligometastatic Prostate Cancer (OMPC)
Novartis Pharmaceuticals450 enrolled142 locationsNCT05939414
Recruiting
Not Applicable

Hypofractionated Radiosurgery for Localised Prostate Cancer (HYPOSTAT-III)

Prostate Cancer
University Hospital Schleswig-Holstein175 enrolled6 locationsNCT06914544
Recruiting

A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis
Novartis Pharmaceuticals800 enrolled127 locationsNCT05344469
Recruiting
Phase 3

Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody

Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a
Heidelberg University100 enrolled12 locationsNCT05045664
Recruiting
Phase 3

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals Inc.150 enrolled26 locationsNCT07144163
Recruiting
Phase 3

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

Acromegaly
Debiopharm International SA119 enrolled71 locationsNCT06930625
Recruiting

Pompe Disease Registry Protocol

Pompe DiseaseGlycogen Storage Disease Type II
Genzyme, a Sanofi Company2,000 enrolled272 locationsNCT00231400
Recruiting
Phase 3

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Summit Therapeutics1,600 enrolled253 locationsNCT05899608
Recruiting
Phase 3

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled324 locationsNCT06136650
Recruiting
Phase 3

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Prostate CancerProstatic Neoplasms
Merck Sharp & Dohme LLC1,440 enrolled281 locationsNCT06925737
Recruiting
Phase 3

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

IC-MPGN
Novartis Pharmaceuticals106 enrolled127 locationsNCT05755386
Recruiting
Phase 2

A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

VEXAS SyndromeVEXAS
Swedish Orphan Biovitrum78 enrolled39 locationsNCT06782373
Recruiting
Phase 2

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

ColitisInflammatory Bowel DiseasesUlcerative Colitis
Spyre Therapeutics, Inc.645 enrolled175 locationsNCT07012395
Recruiting
Phase 3

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

Arthritis, Psoriatic
MoonLake Immunotherapeutics AG600 enrolled135 locationsNCT06641089